OMO1.01.02

• Research type

  Research Study

• Full title

  A modular, multi-arm, multi-part, first time in patient study to evaluate the safety and tolerability of OMO-1, alone and in combination with anti-cancer treatments, in patients with locally advanced, unresectable or metastatic solid malignancies

• IRAS ID

  225742

• Contact name

  Sarah Patricia Blagden

• Contact email

  sarah.blagden@oncology.ox.ac.uk

• Sponsor organisation

  OCTIMET Oncology NV

• Eudract number

  2017-000878-11

• Duration of Study in the UK

  2 years, 2 months, 28 days

• Research summary

  A clinical study to investigate study drug OMO-1 with patients diagnosed with advanced inoperable or metastatic cancer.

• REC name

  South Central - Oxford C Research Ethics Committee

• REC reference

  17/SC/0229

• Date of REC Opinion

  8 Jun 2017

• REC opinion

  Further Information Favourable Opinion